<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00405249</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-443-014A</org_study_id>
    <nct_id>NCT00405249</nct_id>
  </id_info>
  <brief_title>Safety Study of Elvucitabine in HIV-1 Subjects</brief_title>
  <official_title>14-Day Randomized Double-Blind Comparative Viral Kinetic Study of Elvucitabine Versus Lamivudine Once Daily to HIv-1 Subjects With M184V</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <brief_summary>
    <textblock>
      The purpose of this 28 day study is to assess the viral kinetics and safety of elvucitabine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 14 day on treat/14 day off treatment randomized, double blind viral kinetic study&#xD;
      of elvucitabine versus lamivudine administered once daily to HIV infected subjects with a&#xD;
      documented M184V variant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Anticipated">5</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elvucitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV infected, clinically stable, adults&#xD;
&#xD;
          -  HIVRNA 5000 -150,000, CD4 100&#xD;
&#xD;
          -  Genotypically documented M184V variant&#xD;
&#xD;
          -  Receiving stable ART.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hep B&#xD;
&#xD;
          -  HIV-1 genotype for 4 protease inhibitors&#xD;
&#xD;
          -  HIV-1 genotype positive for 2 NNRTI mutations&#xD;
&#xD;
          -  Previous therapy with system myelosuppressive potential within 3 months of study start&#xD;
&#xD;
          -  Use of Epogen or Neupogen&#xD;
&#xD;
          -  History of cirrhosis&#xD;
&#xD;
          -  Alcohol or drug dependence&#xD;
&#xD;
          -  Inability to tolerate oral medication&#xD;
&#xD;
          -  Women who are pregnant or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Squires, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>November 29, 2006</study_first_submitted>
  <study_first_submitted_qc>November 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2006</study_first_posted>
  <last_update_submitted>February 3, 2009</last_update_submitted>
  <last_update_submitted_qc>February 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2009</last_update_posted>
  <keyword>HIV-1</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexelvucitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

